🚨Now recruiting at the DDU: IDOL, a Phase I/Ib trial for ovarian cancer, testing Idetrexed + Olaparib. Help shape the future of ovarian cancer care. 📍Royal Marsden, Sutton 🔗 ClinicalTrials.gov (NCT06976892) #OvarianCancer #IDOLTrial #DDU #ICR #CancerResearch #TargetedTherapy

🚨 Now recruiting at the DDU: ASpiRE, a Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC), testing SX-682 + Apalutamide. Help shape the future of prostate cancer care. 📍Royal Marsden, Sutton 🔗ClinicalTrials.gov (NCT07002320) #ProstateCancer #ASpiRETrial #DDU #ICR

Happy #InternationalClinicalTrialsDay! 🎉 At DDU-IIT @icr.ac.uk , we’re proud to help turn cutting-edge science into real-world impact. 🔬🌍 To the patients, families & teams behind every trial—your courage fuels the future of medicine. ❤️‍🔥 #ClinicalTrialsDay #ICR #RoyalMarsden #ResearchMatters#ACRP

FDA grants accelerated approval for Avmapki™ + Fakzynja™ in KRAS-mutant LGSOC. The decision was supported by Phase 1 FRAME trial led by Prof. Udai Banerji and RAMP 201 led by Prof. Susana Banerjee. Our thanks to all the patients & their families. #VerastemOncology, #ICR, #RoyalMarsden

🚀 Trial Opportunity! Phase I POTENT trial is recruiting at 4 UK sites—evaluating tepotinib (MET inhibitor) + pembrolizumab (immunotherapy) in NSCLC. 🔍 We warmly invite clinicians to refer suitable patients! 📄 More info: clinicaltrials.gov/NCT05782361 #LungCancer #ClinicalTrials

Our Investigator Initiated Trial, POTENT, presented at #ELCC2025 by Dr Anna Minchom combines tepotinib + pembrolizumab to tackle immune resistance in NSCLC. Promising early results prelude to expanding treatment options & improving outcomes for NSCLC patients. #LungCancer #DDUIIT